Jasper Therapeutics (JSPR): which funds own it

Who owns Jasper Therapeutics?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Velan Capital Investment Management, 9.9% (13G filed Aug 17, 2026), T. Rowe Price Investment Management, 7.1% (13G filed Nov 14, 2025), Bank of America, 6.4% (13G filed Oct 28, 2026) and Anders Hove, 5.3% (13G/A filed Jan 26, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were Velan Capital Investment Management (9.5% of the shares), Acorn Capital Advisors (5.1%) and Kingdon Capital Management, L.l.c (4.8%).

Sources:13G by Velan Capital Investment Management (Aug 17, 2026) ↗13G by T. Rowe Price Investment Management (Nov 14, 2025) ↗13G by Bank of America (Oct 28, 2026) ↗13G/A by Anders Hove (Jan 26, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 11, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

• Velan Capital Investment Management2.7 MType not verified · 8.02% of the company0
• Acorn Capital Advisors1.4 MType not verified · 4.32% of the company+27 K
• Kingdon Capital Management, L.l.c1.4 MInvestment firm · 4.06% of the company0
• Vanguard Capital Management1.2 MIndex manager · 3.52% of the company−576
• Rock Springs Capital Management1.1 MType not verified · 3.31% of the company0
• Carlyle Group1.1 MPrivate equity or venture capital · 3.20% of the company0
• GSA Capital Partners LLP535 KType not verified · 1.61% of the company+516 K
• Millennium Management487 KQuant or multi-manager · 1.46% of the company−1.1 M
• Lion Point Capital465 KType not verified · 1.40% of the company0
• Geode Capital Management264 KIndex manager · 0.79% of the company−54 K

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 42.9% of the shares · top 10: 37.7% · in index firms: 15.3% of the institutional total

Shares reported by the 43 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 11, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Shares outstanding: buybacks and dilution

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

• Jun 9, 2026Seriousfiling ↗

  Notice of delisting or failure to meet a listing rule (Item 3.01)

• Sep 28, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

• Jul 17, 2026Routinefiling ↗

  Unregistered sale of equity securities (Item 3.02)

• Jul 17, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

• May 21, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

• Jan 7, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

  «Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.